Targeting Human Gastrointestinal Stromal Tumor Cells with a Quadruplex-Binding Small Molecule

M. Gunaratnam, S. Swank, Shozeb Haider, K. Galesa, A.P. Reszka, M. Beltran, F. Cuenca, J.A. Fletcher, S. Neidle

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Most of human gastrointestinal stromal tumors (GIST) are driven by activating mutations in the protooncogene KIT, a tyrosine kinase receptor. Clinical treatment with imatinib targets the kinase domain of KIT, but tumor regrowth occurs as a result of them development of resistant mutations in the kinase active site. An alternative small-molecule approach to GIST therapy is described, in which the KIT gene is directly targeted, and thus, kinase resistance may be circumvented. A naphthalene diimide derivative has been used to demonstrate the concept of dual quadruplex targeting. This compound strongly stabilizes both telomeric quadruplex DNA and quadruplex sites in the KIT promoter in vitro. It is shown here that the compound is a potent inducer of growth arrest in a patient-derived GIST cell line at a concentration (similar to 1 mu M) that also results in effective inhibition of telomerase activity and almost complete suppression of KIT mRNA and KIT protein expression. Molecular modeling studies with a telomeric quadruplex have been used to rationalize aspects of the experimental quadruplex melting data.
Original languageEnglish
Pages (from-to)3774-3783
Number of pages10
JournalJournal of Medicinal Chemistry
Volume52
Issue number12
DOIs
Publication statusPublished - 25 Jun 2009

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Targeting Human Gastrointestinal Stromal Tumor Cells with a Quadruplex-Binding Small Molecule'. Together they form a unique fingerprint.

Cite this